Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T09:43:59.470Z Has data issue: false hasContentIssue false
  • English
  • Français

Reasons for cannabis use in first-episode psychosis: Does strength of endorsement change over 12 months?

Published online by Cambridge University Press:  15 April 2020

A. Kolliakou ,
D. Castle ,
H. Sallis ,
C. Joseph ,
J. O’Connor ,
B. Wiffen ,
C. Gayer-Anderson ,
G. McQueen ,
H. Taylor  and
S. Bonaccorso
...Show all authors
A. Kolliakou*
Affiliation:
Department of Psychological Medicine, PO92, Institute of Psychiatry, King's College London, De Crespigny Park, SE5 8AFLondon, UK
D. Castle
Affiliation:
Department of Psychiatry, University of Melbourne, Melbourne, Australia
H. Sallis
Affiliation:
MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, UK
C. Joseph
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
J. O’Connor
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
B. Wiffen
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
C. Gayer-Anderson
Affiliation:
Department of Health Service and Population Research, Institute of Psychiatry, King’s College London, London, UK
G. McQueen
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
H. Taylor
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
S. Bonaccorso
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
F. Gaughran
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
S. Smith
Affiliation:
Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, King’s College London, London, UK
K. Greenwood
Affiliation:
School of Psychology, University of Sussex, Sussex, UK
R.M. Murray
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
M. Di Forti
Affiliation:
Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
Z. Atakan
Affiliation:
Department of Neuroimaging, Institute of Psychiatry, King’s College London, London, UK
K. Ismail
Affiliation:
Department of Psychological Medicine, PO92, Institute of Psychiatry, King's College London, De Crespigny Park, SE5 8AFLondon, UK
*
*Corresponding author. Tel.: +44 0 2032288561. E-mail address:anna.kolliakou@kcl.ac.uk (A. Kolliakou).
Get access

Abstract

Background:

Why patients with psychosis use cannabis remains debated. The self-medication hypothesis has received some support but other evidence points towards an alleviation of dysphoria model. This study investigated the reasons for cannabis use in first-episode psychosis (FEP) and whether strength in their endorsement changed over time.

Methods:

FEP inpatients and outpatients at the South London and Maudsley, Oxleas and Sussex NHS Trusts UK, who used cannabis, rated their motives at baseline (n = 69), 3 months (n = 29) and 12 months (n = 36). A random intercept model was used to test the change in strength of endorsement over the 12 months. Paired-sample t-tests assessed the differences in mean scores between the five subscales on the Reasons for Use Scale (enhancement, social motive, coping with unpleasant affect, conformity and acceptance and relief of positive symptoms and side effects), at each time-point.

Results:

Time had a significant effect on scores when controlling for reason; average scores on each subscale were higher at baseline than at 3 months and 12 months. At each time-point, patients endorsed ‘enhancement’ followed by ‘coping with unpleasant affect’ and ‘social motive’ more highly for their cannabis use than any other reason. ‘Conformity and acceptance’ followed closely. ‘Relief of positive symptoms and side effects’ was the least endorsed motive.

Conclusions:

Patients endorsed their reasons for use at 3 months and 12 months less strongly than at baseline. Little support for the self-medication or alleviation of dysphoria models was found. Rather, patients rated ‘enhancement’ most highly for their cannabis use.

Keywords

PsychosisSchizophreniaCannabis useReasons for cannabis useSelf-medicationAlleviation of dysphoria
Type
Original article
Information
European Psychiatry , Volume 30 , Issue 1 , January 2015 , pp. 152 - 159
Copyright
Copyright © European Psychiatric Association 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, J, Duchak, V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand 1997;96:329–333.CrossRefGoogle Scholar
Archie, S, Boydell, KM, Stasiulis, E, Volpe, T, Gladstone, BM. Reflections of young people who have had a first episode of psychosis: what attracted them to use alcohol and illicit drugs?. Early Interv Psychiatry 2013;7(2):193–199.CrossRefGoogle ScholarPubMed
Bahorik, AL, Newhill, CE, Queen, CC, Eack, SM. Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychol Med 2014;44(1):61–69.CrossRefGoogle ScholarPubMed
Baigent, M, Holme, G, Hafner, RJ. Self-reports of the interaction between substance abuse and schizophrenia. Aust N Z J Psychiatry 1995;29(1):69–74.CrossRefGoogle Scholar
Barnett, JH, Werners, U, Secher, SM, Hill, KE, Brazil, R, Masson, K, et al.Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007;190:515–520.CrossRefGoogle Scholar
Cooper, ML. Motivations for alcohol use among adolescents: development and validation of a four-factor model. Psychol Assess 1994;6:117–128.CrossRefGoogle Scholar
Dixon, L, Haas, G, Weiden, PJ, Sweeney, J, Frances, AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991;148:224–230.Google ScholarPubMed
Donovan, DM, Bigelow, GE, Brigham, GS, Carroll, KM, Cohen, AJ, Gardin, JG, et al.Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 2012;107(4):694–708.CrossRefGoogle ScholarPubMed
Fowler, IL, Carr, VJ, Carter, NT, Lewin, TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998;24:443–445.CrossRefGoogle Scholar
Goswami, S, Mattoo, SK, Basu, D, Sing, G. Substance-abusing schizophrenics: do they self-medicate?. Am J Addict 2004;13:139–150.CrossRefGoogle ScholarPubMed
Grech, A, Van Os, J, Jones, PB, Lewis, SW, Murray, RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005;20(4):349–353.CrossRefGoogle ScholarPubMed
Green, B, Kavanagh, DJ, Young, R.M.C.D.. Reasons for cannabis use in men with or without psychosis. Drug Alcohol Rev 2004;23:445–453.CrossRefGoogle ScholarPubMed
Green, B, Young, R, Kavanagh, D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005;187:306–313.CrossRefGoogle ScholarPubMed
Gregg, L, Barrowclough, C, Haddock, G. Reasons for increased substance use in psychosis. Clin Psychol Rev 2007;27:494–510.CrossRefGoogle ScholarPubMed
Gregg, L, Haddock, G, Barrowclough, C. Self-reported reasons for substance use in schizophrenia: a Q methodological investigation. Ment Health Subst Use 2009;2(1):24–39.CrossRefGoogle Scholar
Harrison, I, Joyce, EM, Mutsatsa, SH, Hutton, SB, Huddy, V, Kapasi, M, et al.Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med 2007;38:79–88.CrossRefGoogle ScholarPubMed
Hides, L, Dawe, S, Kavanagh, DJ, Young, RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 2006;189:137–143.CrossRefGoogle ScholarPubMed
Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.CrossRefGoogle Scholar
Khantzian, EJ. The self-medication hypothesis of addictive disorders. Am J Psychiatry 1985;142:1259–1264.Google ScholarPubMed
Khantzian, EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4:231–244.CrossRefGoogle ScholarPubMed
Kolliakou, A, Joseph, C, Atakan, A, Ismail, K, Murray, RM. Why do patients with psychosis use cannabis and are they ready to change their use?. Int J Dev Neurosci 2011;29:335–346.CrossRefGoogle ScholarPubMed
Kolliakou, A, Ismail, K, Fusar-Poli, P, Atakan, Z. Why do psychotic patients use cannabis? Case series. Curr Pharm Des 2012;18:4950–4959.CrossRefGoogle ScholarPubMed
Kot, T, Serper, M. Increased susceptibility to auditory conditioning in hallucinating schizophrenic patients: a preliminary investigation. J Nerv Ment Dis 2002;190:282–288.CrossRefGoogle ScholarPubMed
Laudet, AB, Magura, S, Vogel, HS, Knight, EL. Perceived reasons for substance misuse among persons with a psychiatric disorder. Am J Orthopsychiatry 2004;74(3):365–375.CrossRefGoogle ScholarPubMed
Leucht, S, Kane, JM, Kissling, W, Hamann, J, Etscel, E, Engel, RR. What does the PANSS mean?. Schizophr Res 2005;79(2–3):231–238.CrossRefGoogle ScholarPubMed
Linszen, DH, Dingemans, PM, Lenior, ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51(4):273–279.CrossRefGoogle ScholarPubMed
McCreadie, RG. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 2002;181:321–325.CrossRefGoogle ScholarPubMed
McHugo, GJ, Drake, RE, Brunette, MF, Haiyi Xie, , Essok, SM, Green, AI. Enhancing validity in co-occurring disorders treatment research. Schizophr Bull 2006;32(4):655–665.CrossRefGoogle ScholarPubMed
Miles, H, Johnson, S, Amponsah-Afuwape, S, Finch, E, Leese, M, Thornicroft, G. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv 2003;54:554–561.CrossRefGoogle Scholar
Mueser, KT, Drake, RE, Wallach, MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998;23(6):717–734.CrossRefGoogle ScholarPubMed
Statistical Package for the Social Sciences. Version 20 for Windows. Chicago: SPSS Inc; 2011.Google Scholar
Pencer, A, Addington, J. Reasons for using substances in adolescents with and without psychosis. Early Interv Psychiatr 2008;2:42–44.CrossRefGoogle ScholarPubMed
Pérez, LG, Santacana, AM, Baquero, DB, Pérez-Solá, V. Reasons and subjective effects of cannabis use among people with psychotic disorders: a systematic review. Actas Esp Psiquiatr 2014;42(2):83–90.Google Scholar
Regier, DA, Farmer, ME, Rae, DS, Locke, BZ, Keith, SJ, Judd, LL, et al.Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511–2518.CrossRefGoogle ScholarPubMed
Schaub, M, Fanghaenel, K, Stohler, R. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. Aust N Z J Psychiatry 2008;42:1060–1065.CrossRefGoogle ScholarPubMed
Schneier, FR, Siris, SG. A review of psychoactive substance use and abuse in schizophrenia patterns of drug choice. J Nerv Ment Dis 1987;175(11):641–652.CrossRefGoogle ScholarPubMed
Schofield, D, Tennant, C, Nash, L, Degenhardt, L, Cornish, A, Hobbs, C, et al.Reasons for cannabis use in psychosis. Aust N Z J Psychiatry 2006;40:570–574.CrossRefGoogle ScholarPubMed
Seddon, LJ, Copello, A, Birchwood, M. Cannabis use and abstention in first-episode psychosis: the participants’ view. Mental Health Subst Use 2013;6(1):47–58.CrossRefGoogle Scholar
Selten, JP, Bosman, IJ, de Boer, D, Veen, ND, van der Graaf, Y, Maes, RA, et al.Hair analysis for cannabinoids and amphetamines in a psychosis incidence study. Eur Neuropsychopharmacol 2002;12:27–30.CrossRefGoogle Scholar
Sevy, S, Robinson, DG, Solloway, S, Alvir, JM, Woerner, MG, Bilder, R, et al.Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001;104:367–374.CrossRefGoogle ScholarPubMed
Sorbara, F, Liraud, F, Assens, F, Abalan, F, Verdoux, H. Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur Psychiatry 2003;18:133–136.CrossRefGoogle ScholarPubMed
Spencer, C, Castle, D, Michie, PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002;28(2):233–247.CrossRefGoogle ScholarPubMed
Spencer, C, Castle, D, Michie, PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002;28:233–247.CrossRefGoogle ScholarPubMed
Swartz, MS, Swanson, JW, Hannon, MJ. Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair. Psychiatr Serv 2003;54(6):891–895.CrossRefGoogle ScholarPubMed
Swendsen, J, Ben-Zeev, D, Granholm, E. Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am J Psychiatry 2011;168(2):202–209.CrossRefGoogle Scholar
Test, MA, Wallisch, LS, Allness, DJ, Ripp, K. Substance use in young adults with schizophrenic disorders. Schizophr Bull 1989;15(3):465–476.CrossRefGoogle ScholarPubMed
Thornton, LK, Baker, AL, Lewin, TJ, Kay-Lambkin, FJ, Kavanagh, D, Richmond, R, et al.Reasons for substance use among people with mental disorders. Addict Behav 2012;37:427–434.CrossRefGoogle ScholarPubMed
Tietz, NWTextbook of Clinical Chemistry. W.B. Saunders Company; 1986.Google Scholar
Wolford, GL, Rosenberg, SD, Drake, RE, Mueser, KT, Oxman, TE, Hoffman, D, et al.Evaluation of methods for detecting substance use disorder in persons with severe mental illness. Psychol Addict Behav 1999;13:313–326.CrossRefGoogle Scholar
Zammit, S, Moore, TH, Lingford-Huges, A, Barnes, TR, Jones, PB, Burke, M, et al.Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008;193(5):357–363.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.